BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside China.
The new approval covers three separate indications for the drug, alone and in combination with chemotherapy for squamous and non-squamous forms of NSCLC, and covering first- and second-line therapy.
